摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-Methoxy-5-(trifluoromethoxy)phenyl)acetic acid

中文名称
——
中文别名
——
英文名称
2-(3-Methoxy-5-(trifluoromethoxy)phenyl)acetic acid
英文别名
2-[3-methoxy-5-(trifluoromethoxy)phenyl]acetic acid
2-(3-Methoxy-5-(trifluoromethoxy)phenyl)acetic acid化学式
CAS
——
化学式
C10H9F3O4
mdl
——
分子量
250.17
InChiKey
WWBPHPYEDAYIEW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    55.8
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • [EN] HETEROCYCLIC GLUTAMINASE INHIBITORS<br/>[FR] INHIBITEURS DE GLUTAMINASE HÉTÉROCYCLIQUES
    申请人:CALITHERA BIOSCIENCES INC
    公开号:WO2014078645A1
    公开(公告)日:2014-05-22
    Disclosed herein are heterocyclic compounds containing thiadiazole and/or pyridazine rings, as well as pharmaceutical preparations thereof. The compounds herein are further made known to be useful as glutaminase inhibitors with potential uses in treating cancer, immunological and neurological diseases.
    本文披露了含有噻二唑和/或吡嗪烷环的杂环化合物及其制药制剂。本文中的化合物进一步被认为是谷氨酰胺酶抑制剂,在治疗癌症、免疫和神经系统疾病方面具有潜在用途。
  • TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE
    申请人:Calithera Biosciences, Inc.
    公开号:US20150004134A1
    公开(公告)日:2015-01-01
    The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    本发明涉及新型杂环化合物及其制药制剂。本发明还涉及使用所述新型杂环化合物治疗或预防癌症的方法。
  • HETEROCYCLIC GLUTAMINASE INHIBITORS
    申请人:CALITHERA BIOSCIENCES, INC.
    公开号:US20140194421A1
    公开(公告)日:2014-07-10
    The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    本发明涉及新型杂环化合物及其制药制剂。本发明还涉及使用所述新型杂环化合物的方法进行治疗。
  • Heterocyclic glutaminase inhibitors
    申请人:Calithera Biosciences, Inc.
    公开号:US10793535B2
    公开(公告)日:2020-10-06
    The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    本发明涉及新型杂环化合物及其药物制剂。 本发明还涉及使用本发明的新型杂环化合物进行治疗的方法。
  • [EN] TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE<br/>[FR] TRAITEMENT DU CANCER AVEC DES INHIBITEURS HÉTÉROCYCLIQUES DE GLUTAMINASE
    申请人:CALITHERA BIOSCIENCES INC
    公开号:WO2014089048A1
    公开(公告)日:2014-06-12
    The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof and the methods of treating or preventing cancer using the compounds of the invention. Other aspects relate to methods of identifying a cancer patient that may benefit from treatment with a glutaminase inhibitor comprising determining the ratio of glutamate to glutamine, the ratio of glutaminase enzyme to glutamine synthetase or glutaminase activity in cancer cells of the patient.
查看更多